Business Context and Reporting Period
This Form 6-K filing by GSK plc, dated April 13, 2026, serves as a transaction notification for the month of April 2026. The document details share acquisitions by Persons Discharging Managerial Responsibilities (PDMRs) and Persons Closely Associated (PCAs) resulting from dividend reinvestment plans.
Key Financial Metrics
The filing does not provide consolidated financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. It exclusively reports on specific equity transactions.
| Instrument | Transaction Type | Transaction Dates | Price Range (GBP) | Total Volume (Shares) |
|---|---|---|---|---|
| Ordinary Shares (31 1/2 pence each) | Acquisition via Dividend Reinvestment | April 9–10, 2026 | £21.5039 – £21.6967 | ~19,863 |
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document reflects routine compliance disclosures regarding insider shareholdings rather than operational or financial performance changes.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. It is a statutory disclosure of share transactions executed on the London Stock Exchange (XLON).
Investor Verification Checklist
- Verify the total number of shares acquired by PDMRs and PCAs to assess insider confidence levels.
- Confirm the dividend payment date of April 9, 2026, and the corresponding reinvestment execution dates.
- Check the prevailing market price of GSK ordinary shares on April 9 and 10, 2026, against the transaction prices (£21.50–£21.70).
- Review the specific roles of the transacting individuals (e.g., CEO, Presidents, SVPs) to understand the breadth of executive participation.